Results 151 to 160 of about 1,136,066 (284)

Advancing Clinical Research

open access: yes
Advanced Science, EarlyView.
wiley   +1 more source

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

open access: yesArthritis &Rheumatology, EarlyView.
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis   +22 more
wiley   +1 more source

Inferring Rheumatoid Arthritis Disease Activity Status From the Electronic Health Records Across Health Systems

open access: yesArthritis &Rheumatology, EarlyView.
Objective Disease activity plays a central role in rheumatoid arthritis (RA) clinical studies. The inconsistent availability of data on disease activity in real‐world electronic health records (EHRs) data has limited the ability to generate real‐world evidence (RWE).
David Cheng   +34 more
wiley   +1 more source

Transitional care interventions and outcome measures in stroke rehabilitation: a scoping review. [PDF]

open access: yesDisabil Rehabil
Tierney-Hendricks C   +7 more
europepmc   +1 more source

Higher Complement C4 Gene Copy Number Constitutes a Shared Genetic Risk Factor for Giant Cell Arteritis and IgA Vasculitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Low copy number (CN) of complement C4 isoforms and high CN of retroviral HERV‐K elements are known risk factors for many immune‐mediated inflammatory diseases (IMIDs), often showing sex‐biased effects. Here, we assessed whether CN variation within the C4 gene contributes to giant cell arteritis (GCA) and IgA vasculitis (IgAV), two complex ...
Laura Martínez‐Gutiérrez   +295 more
wiley   +1 more source

Long-Term Outcome After Intensive Stroke Rehabilitation. [PDF]

open access: yesJ Clin Med
Geißler M   +4 more
europepmc   +1 more source

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with JAK inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Methods This study used data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis linked to the
Zixing Tian   +8 more
wiley   +1 more source

An upper limb stroke rehabilitation exercise video dataset. [PDF]

open access: yesData Brief
Nandana S   +3 more
europepmc   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy